Skip to contentB
BioMarin Pharmaceutical Inc
B
BMRNBioMarin Pharmaceutical Inc Q3 2019 · 10-Q
Revenue$461.10M$461.10M+17.7% vs Q3 2018 Net Income$55.04M$55.04MN/M vs Q3 2018 EPS Diluted$0.30$0.30N/M vs Q3 2018 Operating Income$4,010,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioMarin Pharmaceutical Inc · CIK 1048477 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$37,271,000N/M Margins · derivedOperating margin0.9%+4.9 pt vs Q3 2018
Net margin11.9%+15.2 pt vs Q3 2018
ended Sep 30, 2019 · filed Oct 29, 2019 · 29 d after period end